Inhibikase Therapeutics IncIKT
Price$1.93

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$48.3MTTM through 30 Jun 2026
Free Cash Flow -$42.6MTTM through 30 Jun 2026

Margins

Current

Returns

-40.2%ROE
-26.6%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio21.70x
Net Debt-$178.8Mnet cash position
Cash & Equivalents$178.8M

Quality Metrics

Altman Z-Score17.39
Piotroski F-Score1 / 9
Earnings-Beat Rate33.3%

Multi-Year Trend

Revenue
'20'21'22'23'24
FY2024: $0
Diluted EPS-$0.44TTM
'21'22'23'24'25
FY2025: $-0.49

Dividend

No dividend

Capital Allocation

R&D Spend$38.2M

Segment Performance

SegmentRevenueYoYOutlook
Pharmaceutical Development$0
View details

The company is focused on advancing its global pivotal Phase 3 IMPROVE-PAH trial across multiple countries.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.